IBRXImmunityBio, Inc.

$8B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12,000-61.3% YoY

Gross Profit

$12,000100.0% margin

Operating Income

-$16M-129800.0% margin

Net Income

-$16M-129883.3% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

-29.4%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$277,000

Balance Sheet

Total Assets

$160M

Total Liabilities

$24M

Stockholders' Equity

$136M

Cash & Equivalents

$18M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12,000	$31,000	-61.3%
Gross Profit	$12,000	$31,000	-61.3%
Operating Income	-$16M	-$24M	+34.0%
Net Income	-$16M	-$24M	+34.1%

IBRX Q3 2019 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena